ES2184149T3 - Paclitaxeles 6-tio sustituidos. - Google Patents
Paclitaxeles 6-tio sustituidos.Info
- Publication number
- ES2184149T3 ES2184149T3 ES97954044T ES97954044T ES2184149T3 ES 2184149 T3 ES2184149 T3 ES 2184149T3 ES 97954044 T ES97954044 T ES 97954044T ES 97954044 T ES97954044 T ES 97954044T ES 2184149 T3 ES2184149 T3 ES 2184149T3
- Authority
- ES
- Spain
- Prior art keywords
- paclitaxeles
- uncle
- substituted
- present
- invention concerns
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000004579 taxol derivatives Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/6551—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring
- C07F9/65512—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring condensed with carbocyclic rings or carbocyclic ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cephalosporin Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3341996P | 1996-12-24 | 1996-12-24 | |
| US3635197P | 1997-01-23 | 1997-01-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2184149T3 true ES2184149T3 (es) | 2003-04-01 |
Family
ID=26709670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES97954044T Expired - Lifetime ES2184149T3 (es) | 1996-12-24 | 1997-12-05 | Paclitaxeles 6-tio sustituidos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5977386A (cg-RX-API-DMAC10.html) |
| EP (1) | EP0960107B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2001507029A (cg-RX-API-DMAC10.html) |
| AT (1) | ATE225341T1 (cg-RX-API-DMAC10.html) |
| AU (1) | AU722684B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2268774A1 (cg-RX-API-DMAC10.html) |
| DE (1) | DE69716135T2 (cg-RX-API-DMAC10.html) |
| DK (1) | DK0960107T3 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2184149T3 (cg-RX-API-DMAC10.html) |
| PT (1) | PT960107E (cg-RX-API-DMAC10.html) |
| WO (1) | WO1998028288A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2289549A3 (en) | 1999-10-01 | 2011-06-15 | Immunogen, Inc. | Immunoconjugates for treating cancer |
| US6362217B2 (en) | 2000-03-17 | 2002-03-26 | Bristol-Myers Squibb Company | Taxane anticancer agents |
| US6656966B2 (en) | 2000-06-22 | 2003-12-02 | Nitromed, Inc. | Nitrosated and nitrosylated taxanes, compositions and methods of use |
| US7351542B2 (en) | 2002-05-20 | 2008-04-01 | The Regents Of The University Of California | Methods of modulating tubulin deacetylase activity |
| DK2286795T3 (en) | 2002-06-26 | 2017-02-06 | Syncore Biotechnology Co Ltd | PROCEDURE FOR PREPARING A Cationic LIPOSOMAL PREPARATION INCLUDING A LIPOPHIL COMPOUND |
| WO2005016241A2 (en) | 2003-05-16 | 2005-02-24 | Intermune, Inc. | Synthetic chemokine receptor ligands and methods of use thereof |
| US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
| WO2006089218A2 (en) | 2005-02-17 | 2006-08-24 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for modulating angiogenesis |
| CA2646156C (en) | 2006-03-22 | 2016-05-24 | Medigene Ag | Treatment of triple receptor negative breast cancer |
| PL217731B1 (pl) | 2006-06-01 | 2014-08-29 | Tomasz Byrski | Sposób wykrywania genetycznie uwarunkowanej obniżonej odpowiedzi na chemioterapię cytostatykiem taksanowym, zastosowanie mutacji założycielskiej oraz zestawu do wykrywania takiej odpowiedzi |
| EP2859916B1 (en) | 2008-05-22 | 2017-11-29 | Galera Labs, LLC | Combination of an antimitotic agent and a selective superoxide dismutase mimetic in antitumor therapy |
| WO2010005850A1 (en) | 2008-07-08 | 2010-01-14 | The J. David Gladstone Institutes | Methods and compositions for modulating angiogenesis |
| CN102040570B (zh) * | 2009-10-14 | 2014-07-30 | 江苏先声药物研究有限公司 | 硫代紫杉烷类衍生物及其制备方法和用途 |
| EP2874650A4 (en) | 2012-07-19 | 2016-03-23 | Redwood Bioscience Inc | FOR CD22 SPECIFIC ANTIBODIES AND METHOD FOR USE THEREOF |
| CN104884056A (zh) | 2012-11-12 | 2015-09-02 | 雷德伍德生物科技股份有限公司 | 用于制备缀合物的化合物和方法 |
| KR102132246B1 (ko) | 2013-02-15 | 2020-07-09 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 키메라 항원 수용체 및 이의 이용 방법 |
| JP6410790B2 (ja) | 2013-03-14 | 2018-10-24 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | ミトコンドリアアルデヒドデヒドロゲナーゼ−２調節因子およびその使用方法 |
| AU2014354643B2 (en) | 2013-11-27 | 2020-03-05 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
| WO2015127137A1 (en) | 2014-02-19 | 2015-08-27 | Aldea Pharmaceuticals, Inc. | Mitochondrial aldehyde dehydrogenase 2 (aldh2) binding polycyclic amides and their use for the treatment of cancer |
| CN106459200B (zh) | 2014-03-21 | 2019-12-06 | 艾伯维公司 | 抗-egfr抗体及抗体药物偶联物 |
| US10654875B2 (en) | 2015-11-12 | 2020-05-19 | The Board Of Trustees Of The Leland Stanford Junior University | Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery |
| US20210206826A1 (en) | 2015-11-19 | 2021-07-08 | The Regents Of The University Of California | Conditionally repressible immune cell receptors and methods of use thereof |
| TWI760319B (zh) | 2015-12-30 | 2022-04-11 | 杏國新藥股份有限公司 | 乳癌治療 |
| EP3231421A1 (en) | 2016-04-11 | 2017-10-18 | Greenaltech, S.L. | Uses of a carotenoid in the treatment or prevention of stress induced conditions |
| EP3448885A4 (en) | 2016-04-26 | 2020-01-08 | R.P. Scherer Technologies, LLC | ANTIBODY CONJUGATES AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| IL312621A (en) | 2016-06-01 | 2024-07-01 | Servier Ip Uk Ltd | Compositions of polyalkylene oxide-asparaginase and methods for their preparation and use |
| BR112018075630A2 (pt) | 2016-06-08 | 2019-03-19 | Abbvie Inc. | anticorpos anti-cd98 e conjugados de fármaco de anticorpo |
| EP3468599A2 (en) | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| UY37278A (es) | 2016-06-08 | 2018-01-31 | Abbvie Inc | Anticuerpos anti-b7-h3 y conjugados de fármaco y anticuerpos |
| WO2017214322A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
| AU2017279554A1 (en) | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-B7-H3 antibodies and antibody drug conjugates |
| TWI852903B (zh) | 2017-01-05 | 2024-08-21 | 杏國新藥股份有限公司 | 胰臟癌治療 |
| CN110177808A (zh) | 2017-01-18 | 2019-08-27 | F1肿瘤医学公司 | 针对axl或ror2的嵌合抗原受体及其使用方法 |
| EP3388082A1 (en) | 2017-04-13 | 2018-10-17 | Galera Labs, LLC | Combination cancer immunotherapy with pentaaza macrocyclic ring complex |
| EP3630189A4 (en) | 2017-05-24 | 2021-06-23 | The Board of Regents of The University of Texas System | LINKER FOR ANTIBODY MEDICINAL CONJUGATES |
| CN110003142A (zh) * | 2018-01-04 | 2019-07-12 | 深圳福山生物科技有限公司 | 一种硒氰化合物及其用途 |
| JP2021512110A (ja) | 2018-01-31 | 2021-05-13 | ガレラ・ラブス・リミテッド・ライアビリティ・カンパニーGalera Labs, Llc | ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法 |
| WO2019195596A1 (en) | 2018-04-06 | 2019-10-10 | The Regents Of The University Of California | Methods of treating glioblastomas |
| EP3773632A4 (en) | 2018-04-06 | 2022-05-18 | The Regents of The University of California | Methods of treating egfrviii expressing glioblastomas |
| JP2021521173A (ja) | 2018-04-11 | 2021-08-26 | オハイオ・ステイト・イノベーション・ファウンデーション | 眼内薬物送達用の持続放出微粒子のための方法及び組成物 |
| EP3823674A4 (en) | 2018-07-18 | 2022-12-28 | Manzanita Pharmaceuticals, Inc. | CONJUGATES FOR DELIVERING AN ANTI-CANCER AGENT TO NERVE CELLS, METHODS OF USE AND METHODS OF PRODUCTION THEREOF |
| CN113692413A (zh) | 2019-04-02 | 2021-11-23 | 肯乔克蒂生物技术股份有限公司 | 外排泵-癌症抗原多特异性抗体以及与其相关的组合物、试剂、试剂盒和方法 |
| MX2022009355A (es) | 2020-01-29 | 2022-09-02 | Kenjockety Biotechnology Inc | Anticuerpo anti-mdr1 y uso del mismo. |
| JP7768902B2 (ja) | 2020-06-04 | 2025-11-12 | ウィリアム ロバート アラスーン リビング トラスト デイテッド オーガスト 29, 2016 | Ａｂｃｇ２排出ポンプ－がん抗原多重特異性抗体並びにそれらに関連する組成物、試薬、キット、及び方法 |
| US20230212305A1 (en) | 2020-06-04 | 2023-07-06 | Kenjockety Biotechnology, Inc. | Anti-abcg2 antibodies and uses thereof |
| CA3193588A1 (en) | 2020-09-02 | 2022-03-10 | Kenjockety Biotechnology, Inc. | Anti-abcc1 antibodies and uses thereof |
| AU2021380659A1 (en) | 2020-11-13 | 2023-06-01 | Kenjockety Biotechnology, Inc. | Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof |
| AU2021382033A1 (en) | 2020-11-20 | 2023-06-22 | R.P. Scherer Technologies, Llc | Glycoside dual-cleavage linkers for antibody-drug conjugates |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| EP4448007A1 (en) | 2021-12-13 | 2024-10-23 | William Robert Arathoon Living Trust Dated August 29, 2016 | Anti-abcb1 antibodies |
| WO2023159220A1 (en) | 2022-02-18 | 2023-08-24 | Kenjockety Biotechnology, Inc. | Anti-cd47 antibodies |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2601675B1 (fr) * | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
| US4876399A (en) * | 1987-11-02 | 1989-10-24 | Research Corporation Technologies, Inc. | Taxols, their preparation and intermediates thereof |
| US4960790A (en) * | 1989-03-09 | 1990-10-02 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
| US5714512A (en) * | 1991-07-08 | 1998-02-03 | Rhone-Poulenc Rorer, S.A. | Compositions containing taxane derivatives |
| CA2119363C (en) * | 1991-09-23 | 2001-07-17 | Robert A. Holton | 10-desacetoxytaxol derivatives |
| US5272171A (en) * | 1992-02-13 | 1993-12-21 | Bristol-Myers Squibb Company | Phosphonooxy and carbonate derivatives of taxol |
| AU672006B2 (en) * | 1992-04-17 | 1996-09-19 | Abbott Laboratories | Taxol derivatives |
| US5294637A (en) * | 1992-07-01 | 1994-03-15 | Bristol-Myers Squibb Company | Fluoro taxols |
| US5254580A (en) * | 1993-01-19 | 1993-10-19 | Bristol-Myers Squibb Company | 7,8-cyclopropataxanes |
| FR2697019B1 (fr) * | 1992-10-15 | 1994-11-25 | Rhone Poulenc Rorer Sa | Nouveaux dérivés du taxane, leur préparation et les compositions pharmaceutiques qui les contiennent. |
| CA2109861C (en) * | 1992-12-04 | 1999-03-16 | Shu-Hui Chen | 6,7-modified paclitaxels |
| JP3492690B2 (ja) * | 1992-12-23 | 2004-02-03 | ブリストル‐マイアーズ スクイブ カンパニー | 新規な側鎖をもつタキサン類およびその中間体類 |
| MX9308012A (es) * | 1992-12-24 | 1994-08-31 | Bristol Myers Squibb Co | Eteres fosfonooximetilicos de derivados de taxano, solubles en agua y composiciones farmaceuticas que los incluyen. |
| ES2193154T3 (es) * | 1993-03-05 | 2003-11-01 | Univ Florida State | Procedimiento para la preparacion de 9-desoxotaxanos. |
| US5703247A (en) * | 1993-03-11 | 1997-12-30 | Virginia Tech Intellectual Properties, Inc. | 2-Debenzoyl-2-acyl taxol derivatives and methods for making same |
| SI0703909T1 (en) * | 1993-06-11 | 2000-08-31 | Pharmacia & Upjohn Company | Delta 6,7 -taxols antineoplastic use and pharmaceutical compositions containing them |
| CA2192373A1 (en) * | 1994-06-09 | 1995-12-14 | Hirofumi Terasawa | Deacetoxytaxol derivative |
| NZ288802A (en) * | 1994-06-28 | 1998-05-27 | Upjohn Co | Ether taxol derivatives, preparation and pharmaceutical compositions thereof |
| ES2126919T3 (es) * | 1994-07-26 | 1999-04-01 | Indena Spa | Taxanos semisinteticos con actividad antitumoral. |
-
1997
- 1997-11-26 US US08/979,139 patent/US5977386A/en not_active Expired - Fee Related
- 1997-12-05 ES ES97954044T patent/ES2184149T3/es not_active Expired - Lifetime
- 1997-12-05 PT PT97954044T patent/PT960107E/pt unknown
- 1997-12-05 JP JP52877098A patent/JP2001507029A/ja not_active Abandoned
- 1997-12-05 EP EP97954044A patent/EP0960107B1/en not_active Expired - Lifetime
- 1997-12-05 CA CA002268774A patent/CA2268774A1/en not_active Abandoned
- 1997-12-05 AT AT97954044T patent/ATE225341T1/de not_active IP Right Cessation
- 1997-12-05 WO PCT/US1997/022152 patent/WO1998028288A1/en not_active Ceased
- 1997-12-05 DK DK97954044T patent/DK0960107T3/da active
- 1997-12-05 DE DE69716135T patent/DE69716135T2/de not_active Expired - Fee Related
- 1997-12-05 AU AU57922/98A patent/AU722684B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DE69716135T2 (de) | 2003-06-05 |
| CA2268774A1 (en) | 1998-07-02 |
| PT960107E (pt) | 2003-02-28 |
| DK0960107T3 (da) | 2003-02-10 |
| EP0960107A1 (en) | 1999-12-01 |
| EP0960107B1 (en) | 2002-10-02 |
| US5977386A (en) | 1999-11-02 |
| AU722684B2 (en) | 2000-08-10 |
| DE69716135D1 (en) | 2002-11-07 |
| WO1998028288A1 (en) | 1998-07-02 |
| JP2001507029A (ja) | 2001-05-29 |
| AU5792298A (en) | 1998-07-17 |
| EP0960107A4 (cg-RX-API-DMAC10.html) | 1999-12-01 |
| ATE225341T1 (de) | 2002-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2184149T3 (es) | Paclitaxeles 6-tio sustituidos. | |
| DK0971717T3 (da) | Cytotoksiske aminosukker- og relaterede sukkerderivater af indolopyrrolocarbazoler | |
| FI943749A0 (fi) | Taksaanijohdannaisten fosfono-oksimetyylieetterit | |
| CY1108610T1 (el) | Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες | |
| ATE231872T1 (de) | Thiazolopyrimidinderivate | |
| ID23374A (id) | Halogenopirimidin | |
| ES2181744T3 (es) | Hidratos de paclitaxel cristalinos. | |
| TR199800436A3 (tr) | Primidin türevlerinin kanserin önlenmesi için kullanilmasi. | |
| MX9601994A (es) | Profarmacos de derivados de paclitaxel. | |
| SE9904377D0 (sv) | Pharmaceutical combinations | |
| SE9802937D0 (sv) | Novel compounds | |
| ATE250340T1 (de) | 7-methylthiooxomethyl- und 7- methylthiodioxomethyl-paclitaxele | |
| AU4558201A (en) | Taxane anticancer agents | |
| NO20021429L (no) | 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner | |
| ECSP003536A (es) | Derivados de rufomicina utiles como antibioticos |